Phenolphthalein carcinogenicity potential to be revisited at April 30 "feedback" meeting.
This article was originally published in The Tan Sheet
Executive Summary
PHENOLPHTHALEIN CARCINOGENICITY POTENTIAL TO BE REVISITED at an FDA OTC "feedback" meeting scheduled for April 30. The meeting will include reconsideration of the OTC laxative ingredient's safety by FDA's Carcinogenicity Assessment Committee, the agency's cancer study review board. The National Toxicology Program will present new transgenic animal data on phenolphthalein at the meeting, which the committee hopes will allow it to make a final determination about the substance's safety.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning